12(S)-HETE induces lymph endothelial cell retraction in vitro by upregulation of SOX18

International Journal of Oncology
Adryan FristiohadyGeorg Krupitza

Abstract

Metastasising breast cancer cells communicate with adjacent lymph endothelia, intravasate and disseminate through lymphatic routes, colonise lymph nodes and finally metastasize to distant organs. Thus, understanding and blocking intravasation may attenuate the metastatic cascade at an early step. As a trigger factor, which causes the retraction of lymph endothelial cells (LECs) and opens entry ports for tumour cell intravasation, MDA-MB231 breast cancer cells secrete the pro-metastatic arachidonic acid metabolite, 12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid [12(S)-HETE]. In the current study, treatment of LECs with 12(S)-HETE upregulated the expression of the transcription factors SRY-related HMG-box 18 (SOX18) and prospero homeobox protein 1 (PROX1), which determine endothelial development. Thus, whether they have a role in LEC retraction was determined using a validated intravasation assay, small interfering RNA mediated knockdown of gene expression, and mRNA and protein expression analyses. Specific inhibition of SOX18 or PROX1 significantly attenuated in vitro intravasation of MDA-MB231 spheroids through the LEC barrier and 12(S)-HETE-triggered signals were transduced by the high and low affinity receptors, 12(S)-HETE r...Continue Reading

References

Sep 3, 1999·The Journal of Biological Chemistry·J YangG S Herron
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Apr 3, 2002·The EMBO Journal·Jeffrey T WigleGuillermo Oliver
Jul 27, 2004·Annals of Surgery·Sebastian F SchoppmannUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Jul 29, 2004·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Sebastian F SchoppmannSilvana Geleff
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gert G Van den EyndenEric A Van Marck
Aug 13, 2008·Expert Opinion on Therapeutic Targets·Matthew BrownCarter Van Waes
Oct 22, 2008·Nature·Mathias FrançoisPeter Koopman
Jun 19, 2010·Blood·Jan KazenwadelNatasha L Harvey
May 25, 2011·Mutation Research·Franziska van ZijlWolfgang Mikulits
Nov 9, 2011·Nature Medicine·Kari Alitalo
Nov 26, 2013·Biochemical and Biophysical Research Communications·José BasílioRainer de Martin
Sep 30, 2014·Molecular Cell·Jonathan D BrownJorge Plutzky
Mar 5, 2016·Nucleic Acids Research·Miriam KlausRalf Jauch
Apr 26, 2016·Oncology Reports·Jianxiang ZhangYuanting Gu
Sep 25, 2016·Biochemical and Biophysical Research Communications·Yazhou WangWeihua Zhu
Oct 26, 2016·Oncology Reports·Mateusz OlbromskiPiotr Dziegiel
Feb 7, 2017·Cell Chemical Biology·Frank FontaineMathias Francois
Apr 11, 2017·International Journal of Oncology·Chi Huu NguyenGeorg Krupitza
Nov 9, 2017·American Journal of Respiratory Cell and Molecular Biology·Christine M GrossStephen M Black
Jan 13, 2018·Nature Reviews. Cancer·Thomas BrabletzRobert A Weinberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

B cells: Gene Expression

B lymphocytes are white blood cells that play a role in the adaptive immune system by secreting antibodies. Here is the latest research on gene expression in B cells.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.